Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase 2 1

Status

Active not recruiting 15Completed 14Withdrawn 7Terminated 7Recruiting 5Suspended 2No longer available 2Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Lymphoma, Large B-Cell, Diffuse 2Prostatic Neoplasms 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 567Specimen Handling 487Carboplatin 456Magnetic Resonance Spectroscopy 442Cyclophosphamide 418Cisplatin 412Radiotherapy 353Gemcitabine 318Bevacizumab 317Paclitaxel 304Biopsy 291Drug Therapy 286Blood Specimen Collection 249Capecitabine 244Oxaliplatin 242fludarabine 238Nivolumab 236venetoclax 227Injections 214Docetaxel 209Fluorouracil 204Dexamethasone 187Radiosurgery 182Rituximab 162Pemetrexed 160Standard of Care 156Surgical Procedures, Operative 148durvalumab 146atezolizumab 146tislelizumab 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Recruiting × tazemetostat × Clear all
NCT07407283 2026-04-21

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 1/2 Recruiting
100 enrolled
Genitourinary

Prostatic Neoplasms

NCT05627232 2026-03-12

Tazemetostat and Palbociclib With CPX-351for R/R AML

Thomas Jefferson University

Phase 1 Recruiting
24 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT05890352 2025-10-20

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

SWOG Cancer Research Network

Phase 2 Recruiting
227 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05372354 2025-09-05

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

Bristol-Myers Squibb

Phase 1/2 Recruiting
260 enrolled
Plasma cell

Multiple Myeloma

NCT05934838 2025-08-15

A Feasibility Trial of Tazemetostat Plus CAR T Cell Therapy in B-cell Lymphomas

Weill Medical College of Cornell University

Phase 1 Recruiting
15 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡